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ABSTRACT
Aim: Conventional soybean lipid emulsions contain no docosahexaenoic acid
(DHA) or arachidonic acid (AA). We investigated the relationship between blood DHA and
AA status in 27 very-low-birth-weight (VLBW) infants with or without parenteral lipid
emulsion.
Methods: Sixteen infants received parenteral lipid emulsion, and 11 infants were
control group. The fatty acid composition of the erythrocyte membrane was analysed at
birth and at 2 weeks of age.
Results: No signiﬁcant difference in AA levels was observed in the lipid emulsion
group between thetwo time points, whereas theAA levels at2 weeks were signiﬁcantly
lower thanat birth inthecontrol group. The DHA levels in bothgroups at2 weeks were
signiﬁcantly lower than atbirth, butno group differences wereobserved at bothtime points.
Conclusion: The use of parenteral soybean oil lipid emulsions in VLBW infants in the
postnatal period may prevent the decline in the AA level but does not appear to inﬂuence
the DHA level.
INTRODUCTION
Preterm infants, especially very-low-birth-weight (VLBW)
infants, often require parenteral lipid emulsion if an ade-
quate energy and lipid intake cannot be achieved by enteral
feeding because their polyunsaturated fatty acids (PUFAs)
body stores are very low, whereas their metabolic require-
ments are high. Therefore, a PUFA supply is of critical
importance (1).
The conventional lipid emulsion for preterm infants is
prepared from long-chain triacylglycerols, mostly soybean
oil. The adequacy of soybean lipid emulsions has been ques-
tioned, primarily in view of the very high concentrations of
linoleic acids (LA; 18:2n-6) and a-linolenic acids (ALA;
18:3n-3) in most commercial preparations. Both of these
PUFAs are metabolized to long-chain PUFA (LCPUFA) by
desaturation and adding extra double bonds to the carboxyl
group end of the molecule.
Docosahexaenoic acid (DHA; 22:6n-3) and arachidonic
acid (AA; 20:4n-6) are the major LCPUFA components of
membrane lipids in the brain and retina (2), making them
essential components of infant nutrition. About 80% of
intrauterine DHA and AA accumulation occurs during the
last 3 months of pregnancy (2). In preterm infants, the intra-
uterine supply of DHA and AA is limited by the early termi-
nation of maternal-to-foetal fatty acid transfer.
Preterm infants are capable of the de novo synthesis of
DHA and AA from the dietary essential precursor fatty
acids LA and ALA (3,4). However, it is unclear whether the
de novo synthesis is sufﬁcient to meet their physiological
requirements. Failure to accumulate sufﬁcient DHA may
impair neurological development (5,6), and clinical evi-
dence supports a relationship between blood AA levels and
infant growth (7,8). Soybean-based lipid emulsions contain
no DHA or AA. On the other hand, the rationale for quanti-
fying LCPUFA levels in RBC membranes is the assumption
that they reﬂect tissue (including brain) DHA and AA con-
centrations (9).
Little is known of the relationship between postnatal
blood DHA and AA levels in VLBW infants with or without
parenteral lipid emulsion. Therefore, we examined the
LCPUFA proﬁle of the erythrocyte membrane during the
early postnatal period and assessed the efﬁcacy and safety
of lipid emulsion in VLBW infants.
MATERIALS AND METHODS
Study population
An observational study was conducted in the NICU of Junt-
endo University Hospital, Tokyo, Japan. Twenty-seven pre-
term infants with birth weights <1500 g were enrolled in
Key notes
• Soybean lipid emulsion contains no DHA or AA.
• It prevents the decline AA level but does not inﬂuence
DHA level in VLBW infants.
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November 2005. The infants did not have major congenital
malformations or metabolic disorders. Gestational age was
estimated from the mother’s last menstrual period and con-
ﬁrmed through foetal ultrasound measurements.
According to our nutritional protocol, feeding was typi-
cally initiated within the ﬁrst 8 h after birth (20 mL⁄kg
divided over eight feedings per day), and the type of feeding
depended on the mother’s willingness or ability to provide
breast milk. When breast milk was unavailable, infants
received a cow’s milk-based premature formula (Soft-Curd
LW
 ; Meiji Milk Products, Tokyo, Japan) containing
LCPUFA. Parenteral nutrition (PN) with dextrose, amino
acids (Preamin-P; Fuso Pharmaceutical Industries Ltd,
Osaka, Japan) and vitamins was started at birth in all
infants. Parenteral lipid emulsion was started from 72 h of
age if the infant could not tolerate a sufﬁcient amount
(under 50% of total water intake) of feeding.
The infants were divided retrospectively into two groups
according to the use of a parenteral lipid infusion. The lipid
emulsion group (16 infants; 10 boys and six girls) received
the parenteral lipid infusion, and the control group (11
infants; ﬁve boys and six girls) did not receive parenteral
lipid emulsion because all infants received sufﬁcient (over 50%
of total water intake) of feeding before 5 days after birth.
In the lipid emulsion group, the administration of
0.60 ± 0.17 g⁄kg per day (Intralipos 20%; Ohtsuka Pharma-
ceutical, Tokyo, Japan) was started from 3 to 8 days (mean
5.1 ± 2.3 days) after birth and continued until the intake of
enteral feeding was over 50% of the total water intake for 4
to 18 days (mean 6.9 ± 3.6 days) with the emulsion level
being increased to 2.0 g⁄kg. The composition of the soybean
oil lipid emulsion is shown in Table 1.
All mothers had similar educational backgrounds and
were between 25 and 38 years of age. The characteristics of
the sampled mothers are presented in Table 2. All were
nonvegetarian and had similar dietary habits for the dura-
tion of the study. No changes in the dietary habits of the
mothers were observed during the study. This study was
approved by the Institutional Review Board of Juntendo
University Hospital, and written informed consent was
obtained from all mothers before inclusion in the study.
Blood sample collection and analysis
Venous blood samples (approximately 600 lL) were col-
lected in EDTA-containing tubes at birth and 2 weeks of
age. The samples were centrifuged at 3000 g for 10 min. The
erythrocyte pellet was washed twice with 0.9% NaCl and
stored at )80 C until analysis.
The following biochemical blood variables were assessed
at birth and 2 weeks of age by routine laboratory tech-
niques: aminotransferase (AST), alanine aminotransferase
(ALT), total bilirubin (T-bil), direct bilirubin (D-bil) and
C-reactive protein (CRP).
Fatty acid composition of the erythrocyte membrane
Erythrocyte lipids were extracted using chloroform and 2-
propanol (7:11), according to the method described by Rose
and Oklander (10). Erythrocyte fatty acids were esteriﬁed
by boron triﬂuoride–methanol. Methyl esters were identi-
ﬁed using gas chromatography (Shimadzu GC-17A; Kyoto
Japan). The composition of each fatty acid was expressed as
the percentage of total fatty acids.
Statistical analyses
The results are presented as the mean ± standard deviation
(SD). Differences between groups were analysed using the
Mann–Whitney U-test. Differences between the two time
points within groups were analysed using paired t-tests. p
Value less than 0.05 was considered statistically signiﬁcant.
All statistical analyses were performed using StatView 5.0
software (Abacus Concepts, Berkeley, CA, USA).
RESULTS
Samples from 27 VLBWIs were analysed, and the patient
characteristics are summarized in Table 2. The mean birth
weight and birth length of the lipid emulsion group were
Table 1 Composition of the soybean oil–lipid emulsion (Intralipos  20%) and infant
formula (Soft-Curd LW ).
Intralipos  20%
Puriﬁed soybean oil 20 mL⁄100 mL
Egg phospholipids 1.2 g⁄100 mL
Glycerol (anhydrous) 2.2 g⁄100 mL
Fatty acid composition (%) Linoleic acid (18:2n-6) 53
a-Linolenic acid (18:3n-3) 7
Oleic acid (18:1n-9) 24
Palmitic acid (saturated fatty acid) 12
Stearic acid (saturated fatty acid) 4
Soft-Curd LW 
Fatty acid composition
(mg⁄100 mL)
Linoleic acid (18:2n-6) 0.45
a-Linolenic acid (18:3n-3) 0.045
Arachidonic acid (20:4n-6) 3
Docosahexaenoic acid
(DHA; 22:6n-3)
9.8
Table 2 General characteristics of pregnant women and offspring in the lipid emul-
sion and control groups (mean ± SD)
Lipid emulsion (n = 16) Control (n = 11)
Pregnant women
Age (years) 30.56 ± 4.02 32.45 ± 4.23
Body weight at delivery (kg) 58.62 ± 6.37 55.39 ± 7.97
Body height (cm) 159.56 ± 7.71 157.27 ± 5.37
Weight of placenta (g) 300.15 ± 82.23 308.89 ± 70.66
Offspring
Sex (M⁄F) 10⁄65 ⁄6
Gestational age (week) 28.87 ± 2.22 30.10 ± 2.32
Birth weight (kg) 0.94 ± 0.26 1.13 ± 0.24*
Body length (cm) 34.63 ± 3.29 36.74 ± 2.77*
Head circumference (cm) 25.62 ± 2.49 26.46 ± 1.76
Apgar score at 5 min 7.87 ± 1.55 8.82 ± 0.75
*p < 0.05 versus the lipid emulsion group.
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ever, no differences in gestational age or head circumfer-
ence were found between the groups. No signiﬁcant
differences in the time of starting enteral nutrition or the
percentage of human milk at 2 weeks were found between
the groups. A signiﬁcant difference in the age of full feeding
and the period of parenteral nutrition was observed
between the groups (Table 3).
At 2 weeks of age, the LA levels were signiﬁcantly higher
in both groups than at birth. No signiﬁcant differences were
observed between the groups at the two time points. The
ARA levels in the lipid emulsion group remained unchanged
throughout the study, whereas the ARA level in the control
group was signiﬁcantly lower at 2 weeks of age compared to
at birth. Furthermore, the AA levels in the control group at
2 weeks were signiﬁcantly lower than in the lipid emulsion
group. No signiﬁcant differences were found in the eicosa-
pentaenoic acid (EPA; 20:5n-3) levels between the time
points or groups. At 2 weeks of age, the DHA levels were sig-
niﬁcantly lower in both groups than at birth. No signiﬁcant
differences were observed betweenthe two groups at the two
time points. The n-6⁄n-3 ratio in both groups at 2 weeks was
signiﬁcantly higher than that at birth, but no between-group
differences were foundat both time points(Fig. 1).
No signiﬁcant differences were observed between the
groups in the incidence of intracranial haemorrhage (IVH),
necrotizing enterocolitis (NEC), period of ventilation, or
the levels of transaminases, bilirubin and C-reactive protein
at 2 weeks (Table 4).
DISCUSSION
Very-low-birth-weight infants are usually treated routinely
with total PN containing dextrose, amino acids, lipid emul-
sions, vitamins and minerals to maintain their nutritional
status with the aim of matching normal intrauterine growth
during the ﬁrst few weeks of life.
Lipids are necessary in neonates receiving PN because of
their high caloric value, low osmolarity and essential fatty
acid (EFA) content (11). However, the endogenous synthe-
sis of LCPUFA from precursor EFA is limited in preterm
infants (12), and the large amounts of LA and ALA in
Table 3 Nutritional management during the postnatal period in the lipid emulsion
and control groups (mean ± SD)
Lipid emulsion (n = 16) Control (n = 11)
Initiation of enteral nutrition (h) 10.63 ± 5.49 9.27 ± 6.69
Age at feeds >100 mL⁄kg per
day (days)
11.69 ± 4.75 7.55 ± 3.77*
Period of parenteral nutrition (days) 12.75 ± 5.84 8.91 ± 3.70*
Human milk⁄enteral nutrition at
2 weeks (%)
91.29 ± 21.55 73.84 ± 39.72
Lipid emulsion
Initiation (day) 5.13 ± 2.31 –
Amount of initiation (g⁄kg per day) 0.60 ± 0.17 –
Period (days) 6.88 ± 3.61 –
Total amount of infusion (g⁄kg) 3.89 ± 3.22 –
*p < 0.05 versus the lipid emulsion group.
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Figure 1 Changes in the fatty acid composition of erythrocytes during the early
postnatal period. *p < 0.05; **p < 0.01 compared to at birth.
Table 4 Clinical characteristics and serum markers of liver dysfunction, jaundice and
sepsis at 2 weeks in the lipid emulsion and control groups
Lipid emulsion
(n = 16) Control (n = 11)
Antenatal steroids 11 6
Intracranial haemorrhage (III, IV) 0 0
Necrotizing enterocolitis 0 0
Sepsis during ﬁrst 2 weeks 1 0
Photocoagulation for retinopathy
of prematurity
11
Period of ventilation (days) 10.64 ± 21.03 10.00 ± 17.18
Oxygen supply at CA 36 weeks
of post-conceptional age
33
At 2 weeks
Aminotransferase (IU⁄L) 19.8 ± 7.27 21.45 ± 6.58
Alanine aminotransferase (IU⁄L) 8.33 ± 3.09 7.91 ± 2.43
Total bilirubin (mg⁄dL) 5.32 ± 2.62 6.33 ± 2.40
Direct-bilirubin (mg⁄dL) 0.84 ± 0.25 1.10 ± 0.46
C-reactive protein (mg⁄dL) 0.06 ± 0.06 0.04 ± 0.05
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tion via substrate inhibition (13,14).
Simmer and Rao (15) reviewed studies investigating the
safety and efﬁcacy of the early introduction of lipid emul-
sions (within the ﬁrst 5 days after birth) to parenterally fed
premature infants. They found no signiﬁcant differences
between the ‘early’ and ‘no early groups’ for the primary
(growth, death and chronic lung disease) and secondary
[incidence of respiratory morbidity, NEC, retinopathy of
prematurity (ROP), sepsis, IVH and jaundice] outcomes.
They concluded that the early introduction of lipids to par-
enteral nutrition cannot be recommended for short-term
growth or to prevent morbidity and mortality in preterm
infants. Nevertheless, because a theoretical beneﬁt of the
early administration of lipid emulsions exists, early intro-
duction may be preferable.
However, concerns have been raised about the early
administration of lipid emulsions because of potential
adverse effects including chronic lung disease, increases in
pulmonary vascular resistance, impaired pulmonary gas
exchange, bilirubin toxicity, sepsis and free radical stress
(16). Lipid emulsions contain different amounts of PUFAs,
which can act as substrates for the formation of lipid hydro-
peroxides, mediated by free radicals. The deleterious effects
of lipid emulsions on the hepatobiliary system have been
suggested recently (11). The accumulation of exogenous lip-
ids in the liver Kupffer cells impairs the clearance of endo-
toxins, and the peroxidation of lipids produces toxic
metabolites (11). Phytosterols contained in lipids emulsions
may also have a deleterious effect on biliary secretions (17).
Shin et al. (18) also demonstrated that the cumulative
amount of lipid infusion was the only signiﬁcant indepen-
dent risk factor of PN-associated cholestasis in preterm
infants.
In this study, we evaluated the incidence of NEC, ROP,
respiratory morbidity, and markers of liver dysfunction,
jaundice and sepsis. We did not see any deleterious effect of
early lipid emulsion. Furthermore, we previously compared
the oxidative stress levels in 23 premature infants by mea-
suring urinary 8-hydroxdeoxyguanosine (8-OHdG; a mar-
ker of oxidative DNA damage) and found no signiﬁcant
differences in the urinary 8-OHdG excretion levels between
the lipid-infused and not-infused groups at 2, 7 and 14 days
of age (19).
As with previous studies (20,21), we found that the levels
of DHA and n-3 PUFA during the ﬁrst 2 weeks decreased
regardless of whether soybean oil lipid emulsion was admin-
istered. Although preterm infants have limited capacity to
convert ALA to DHA, they generally cannot synthesize
enough to prevent declines in cellular DHA concentrations
without additional supplementation. A newer lipid emul-
sion (Omegaven) is made from ﬁsh oil, which contains
LCPUFA (e.g. DHA and EPA). In one study of infants with
short bowel syndrome, the reversal of cholestasis because of
prolonged PN exposure was quicker in 18 infants who
received Omegaven compared to 21 historical controls who
received soybean emulsions (9.4 versus 44 weeks) (22).
Although randomized controlled trials are needed to
determine whether this formulation is more beneﬁcial than
the soybean-based lipid emulsion, it offers new possibilities
for the management of preterm infants with feeding intoler-
ance. However, this formulation is not available for routine
use in Japan.
Our results indicate that parenteral lipid emulsion ﬁrst
administered to VLBW infants around 5 days after birth
prevented the decline in the AA level but did not inﬂuence
the DHA level or n-6⁄n-3 ratio during the early postnatal
period or the short-term clinical outcome. Therefore, we
conclude that under the conditions studied, the administra-
tion of lipid emulsion to VLBW infants appears safe. Fur-
ther research is needed to evaluate the long-term outcomes
on growth, respiratory morbidity and neurodevelopment.
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